Lose sum, win some: Glenmark settles with Texas but can up foreign flows
This article was originally published in Scrip
Executive Summary
Glenmark will pay $25m to settle allegations that it falsely reported inflated drug prices under the Texas Medicaid program, though the firm claims that cash-flows will not be hit "materially".